Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
![Calidi Biotherapeutics Inc - Ordinary Shares logo](/files/LOGO/1855485-placeholder.png)
Company profile
Ticker
CLDI, CLDI-WT
Exchange
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
First Light Acquisition Group, Inc.
SEC CIK
Corporate docs
IRS number
862967193
CLDI stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
15 Jul 24
8-K
Entry into a Material Definitive Agreement
8 Jul 24
8-K
Regulation FD Disclosure
5 Jul 24
8-K
Departure of Directors or Certain Officers
26 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
11 Jun 24
D
$5.55 mm in options / securities to be acquired, sold $5.55 mm, 9 investors
5 Jun 24
424B3
Prospectus supplement
4 Jun 24
8-K
Entry into a Material Definitive Agreement
4 Jun 24
8-K
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
31 May 24
8-K
Departure of Directors or Certain Officers
17 May 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.36 mm | 1.36 mm | 1.36 mm | 1.36 mm | 1.36 mm | 1.36 mm |
Cash burn (monthly) | 268.67 k | (no burn) | 2.41 mm | 2.37 mm | 1.28 mm | 2.31 mm |
Cash used (since last report) | 1.04 mm | n/a | 9.31 mm | 9.17 mm | 4.94 mm | 8.93 mm |
Cash remaining | 322.14 k | n/a | -7.95 mm | -7.81 mm | -3.58 mm | -7.57 mm |
Runway (months of cash) | 1.2 | n/a | -3.3 | -3.3 | -2.8 | -3.3 |
Institutional ownership, Q1 2024
27.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 15.53 mm |
Total shares | 14.20 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Allan Camaisa | 6.10 mm | $0.00 |
Jackson Investment | 2.88 mm | $0.00 |
First Light Acquisition | 2.58 mm | $0.00 |
Scott Leftwich | 1.76 mm | $0.00 |
Funicular Funds | 716.32 k | $6.58 mm |
Cowen And | 172.14 k | $8.95 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jul 24 | George Peoples | NQSO Common stock | Grant | Acquire A | No | No | 0.193 | 30,904 | 5.96 k | 30,904 |
28 Jun 24 | Stewart Alan R. | Common Stock | Grant | Acquire A | No | No | 0 | 73,437 | 0.00 | 154,087 |
28 Jun 24 | Schoeneck James A | Common Stock | Grant | Acquire A | No | No | 0 | 79,687 | 0.00 | 1,071,781 |
28 Jun 24 | Scott Leftwich | Common Stock | Grant | Acquire A | No | No | 0 | 67,187 | 0.00 | 560,873 |
News
Calidi Biotherapeutics Receives Issuance Of New U.S. Patent Covering Novel SuperNova Technology Platform
18 Jul 24
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
8 Jul 24
Why Calidi Biotherapeutics (CLDI) Shares Are Trading Lower
8 Jul 24
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
12 Jun 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Jun 24
Press releases
Calidi to Effect Reverse Stock Split
5 Jul 24
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
11 Jun 24
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
10 Jun 24
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
3 Jun 24
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
31 May 24